Citi analyst Samantha Semenkow reiterated a Buy rating and $14.00 price target on Larimar Therapeutics (NASDAQ: LRMR)The analyst comments "Larimar ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE